A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)
NCT05067790 · ASCEND Phase 3Active, not recruiting
- Lead sponsor
- Biogen (Industry)
- Enrollment
- 45 (actual)
- Start date
- 21 Jan 2022
- Primary completion
- 24 Sep 2027 (estimated)
- Study completion
- 24 Sep 2027
- Last update posted
- 22 May 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None
- Arms
- 1
Interventions
- Nusinersen Drug
Conditions and primary outcome
- Spinal Muscular Atrophy
Primary outcome
Change in Total Revised Upper Limb Module (RULM) Score (Up to Day 855)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT05067790.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT05067790 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.